Isomorphic Laboratories
Total Raised
$600MInvestors Count
4Funding, Valuation & Revenue
2 Fundings
Isomorphic Laboratories has raised $600M over 2 rounds.
Isomorphic Laboratories's latest funding round was a Series A for $600M on March 31, 2025.
Date | Round | Amount | Investors | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Revenue | Sources |
|---|---|---|---|---|---|---|
3/31/2025 | Series A | $600M | Thrive Capital, Alphabet, and Google Ventures | 5 | ||
11/7/2021 | Spinoff / Spinout |
Date | 3/31/2025 | 11/7/2021 |
|---|---|---|
Round | Series A | Spinoff / Spinout |
Amount | $600M | |
Investors | Thrive Capital, Alphabet, and Google Ventures | |
Valuation | ||
Revenue | ||
Sources | 5 |
Isomorphic Laboratories Investors
4 Investors
Isomorphic Laboratories has 4 investors. Google Ventures invested in Isomorphic Laboratories's Series A funding round.
First funding | Last Funding | Investor | Rounds | Board Seats | Type | Location |
|---|---|---|---|---|---|---|
3/31/2025 | 3/31/2025 | 1 Series A | Corporate Venture | California | ||
Venture Capital | New York | |||||
Holding Company | California | |||||
Corporation | United Kingdom |
First funding | 3/31/2025 | |||
|---|---|---|---|---|
Last Funding | 3/31/2025 | |||
Investor | ||||
Rounds | 1 Series A | |||
Board Seats | ||||
Type | Corporate Venture | Venture Capital | Holding Company | Corporation |
Location | California | New York | California | United Kingdom |
Compare Isomorphic Laboratories to Competitors
Insitro is a data-driven drug discovery and development company that utilizes machine learning and high-throughput biology. The company has a machine learning platform that combines in vitro cellular data with human clinical data to identify insights and interventions in metabolism, oncology, and neuroscience. Insitro's approach uses technology to model disease states and design therapeutic interventions. It was founded in 2018 and is based in South San Francisco, California.
Atomwise develops machine learning-based discovery engines and uses artificial intelligence (AI)-based neural networks to help discover new medicines. It predicts drug candidates for pharmaceutical companies, start-ups, and research institutions, and designs drugs using computational drug design. It was formerly known as Chematria. The company was founded in 2012 and is based in San Francisco, California.
BioMap focuses on leveraging artificial intelligence (AI) to advance life sciences. The company develops AI foundation models to understand and predict biological behaviors and creates task models for various life science applications, including therapeutic antibodies and industrial enzymes. BioMap primarily serves the biotechnology and pharmaceutical industries with its AI-driven solutions. It was founded in 2020 and is based in Palo Alto, California.
Healx focused on drug discovery in the healthcare sector. The company specializes in developing treatments for rare diseases by leveraging artificial intelligence and drug development expertise. Healx was formerly known as Healx3. It was founded in 2014 and is based in Cambridge, United Kingdom.
Aitia operates as a biotechnology company. It utilizes causal artificial intelligence (AI), multi-omic patient data, and Gemini Digital Twins to study the biological mechanisms of diseases in the oncology and neurodegenerative disease sectors. The company aims to create computational representations of diseases to assist in the development of therapies. It was founded in 2000 and is based in Somerville, Massachusetts.
Standigm specializes in AI-driven drug discovery within the pharmaceutical industry. The company provides services, including target identification, lead generation, and optimization, as well as AI SaaS solutions for drug development. Standigm primarily serves sectors engaged in pharmaceutical research and drug development. It was founded in 2015 and is based in Seoul, South Korea.
Loading...